201 related articles for article (PubMed ID: 27170571)
1. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
Buttmann M; Seuffert L; Mäder U; Toyka KV
Neurology; 2016 Jun; 86(23):2203-7. PubMed ID: 27170571
[TBL] [Abstract][Full Text] [Related]
2. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
4. Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
Mulroy E; Joyce E; Scott J; Melling J; Goggin C; Mahon N; O'Rourke K; Lynch T
Eur Neurol; 2012; 67(1):45-7. PubMed ID: 22156316
[TBL] [Abstract][Full Text] [Related]
5. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.
Cocco E; Sardu C; Gallo P; Capra R; Amato MP; Trojano M; Uccelli A; Marrosu MG;
Mult Scler; 2008 Nov; 14(9):1225-33. PubMed ID: 18701568
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.
Martinelli V; Cocco E; Capra R; Salemi G; Gallo P; Capobianco M; Pesci I; Ghezzi A; Pozzilli C; Lugaresi A; Bellantonio P; Amato MP; Grimaldi LM; Trojano M; Mancardi GL; Bergamaschi R; Gasperini C; Rodegher M; Straffi L; Ponzio M; Comi G;
Neurology; 2011 Nov; 77(21):1887-95. PubMed ID: 22076543
[TBL] [Abstract][Full Text] [Related]
7. The current role of mitoxantrone in the treatment of multiple sclerosis.
Cocco E; Marrosu MG
Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
[TBL] [Abstract][Full Text] [Related]
8. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
9. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
10. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.
Ghalie RG; Mauch E; Edan G; Hartung HP; Gonsette RE; Eisenmann S; Le Page E; Butine MD; De Goodkin DE
Mult Scler; 2002 Oct; 8(5):441-5. PubMed ID: 12356214
[TBL] [Abstract][Full Text] [Related]
11. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukaemia induced by mitoxantrone: case report.
Arruda WO; Montú MB; de Oliveira Mde S; Ramina R
Arq Neuropsiquiatr; 2005 Jun; 63(2A):327-9. PubMed ID: 16100984
[TBL] [Abstract][Full Text] [Related]
13. Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction.
Joyce E; Mulroy E; Scott J; Melling J; Goggin C; McGorrian C; O'Rourke K; Lynch T; Mahon N
J Card Fail; 2013 Aug; 19(8):571-6. PubMed ID: 23910587
[TBL] [Abstract][Full Text] [Related]
14. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Ellis R; Boggild M
Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone immunotherapy in multiple sclerosis.
Gonsette RE
Mult Scler; 1996 Jul; 1(6):329-32. PubMed ID: 9345411
[TBL] [Abstract][Full Text] [Related]
16. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone-related acute leukemia in two MS patients.
Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
Colovic N; Suvajdzic N; Kraguljac Kurtovic N; Djordjevic V; Dencic Fekete M; Drulovic J; Vidovic A; Tomin D
Biomed Pharmacother; 2012 Apr; 66(3):173-4. PubMed ID: 22440894
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study.
Chaplain G; Milan C; Sgro C; Carli PM; Bonithon-Kopp C
J Clin Oncol; 2000 Aug; 18(15):2836-42. PubMed ID: 10920131
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
